Market: NASD |
Currency: USD
Address: Three International Towers
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
📈 Kazia Therapeutics Limited Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$14.00
-
Upside/Downside from Analyst Target:
91.78%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.200000 |
- |
2025-04-17 |
- |
Stock split |
|
Total Amount for 2025: $0.200000 |
| 2024 |
- |
$0.100000 |
- |
2024-10-28 |
- |
Stock split |
|
Total Amount for 2024: $0.100000 |
| 2017 |
- |
$0.250000 |
- |
2017-07-14 |
- |
Stock split |
|
Total Amount for 2017: $0.250000 |
📅 Earnings & EPS History for Kazia Therapeutics Limited
| Date | Reported EPS |
|---|
| 2025-05-28 | - |
| 2025-05-13 | - |
| 2025-05-05 | - |
| 2025-04-14 | - |
| 2025-03-18 | - |
| 2017-08-30 | - |
| 2017-08-29 | - |
| 2017-02-22 | - |
| 2017-02-21 | - |
| 2016-08-30 | - |
| 2016-08-29 | - |
| 2016-02-22 | - |
| 2016-02-21 | - |
| 2015-08-31 | - |
| 2015-08-30 | - |
| 2015-02-28 | - |
| 2015-02-27 | - |
| 2014-10-03 | - |
| 2014-10-02 | - |
| 2014-02-28 | - |
| 2014-02-27 | - |
📰 Related News & Research
No related articles found for "kazia therapeutics".
